GlassScriptPhysician profile
Michael P Dudenhoeffer
NPI 1073517900
$4,210.08
in general payments reported to CMS, 2019-2025
42 companies · $650 in 2025
The $650 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $208 · 2021: $962 · 2022: $588 · 2023: $975 · 2024: $575 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,129 · Education: $70.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,128.73 |
| Education | $70.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $708.67 | 2019-2023 | Seglentis, Livalo |
| Novo Nordisk INC | $332.13 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Neurocrine Biosciences, INC. | $262.32 | 2021-2025 | Ingrezza |
| Abbvie INC. | $233.61 | 2021-2024 | Vraylar |
| Biohaven Pharmaceuticals, INC. | $201.41 | 2020-2021 | |
| Axsome Therapeutics, INC. | $195.85 | 2024-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $169.83 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $168.98 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $135.96 | 2024-2025 | Zenpep |
| Indivior INC. | $127.34 | 2022-2023 | Perseris |
| Astrazeneca Pharmaceuticals LP | $124.75 | 2019-2025 | Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $121.91 | 2022-2025 | |
| Lundbeck LLC | $106.96 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $105.73 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Astellas Pharma US INC | $94.42 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dudenhoeffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.